PeerVoice Oncology & Haematology Audio PeerVoice
-
- Scienze
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
-
Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC
Visit https://www.peervoice.com/HPP860 to view the entire programme with slides. After completing “Jonathan W. Goldman, MD - Don’t Forget About MET: Keys to Detecting and Targeting MET Alterations as a Therapeutic Vulnerability in NSCLC”, participants will be able to: Differentiate between pathophysiology of MET alterations in patients with NSCLC and the recommended strategies for their detection; Apply best practices to overcome challenges in the identification of patients with NSCLC and MET vulnerabilities; and Summarize current and emerging strategies for targeting MET alterations as a therapeutic vulnerability in patients with NSCLC.
-
Bertrand Tombal, MD, PhD - MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes
Visit https://www.peervoice.com/EUM860 to view the entire programme with slides. After completing “Bertrand Tombal, MD, PhD - MDT Management of Patients Receiving Radioligand Therapy: Strategies to Optimise Outcomes”, participants will be able to: Based on the clinical data, describe what outcomes could be expected to be achieved in men with metastatic castration-resistant prostate cancer (mCRPC) who are eligible for radioligand therapy; Discuss the importance of an effective multidisciplinary team and collaboration in treatment optimisation for patients with mCRPC; Describe adverse events that may be associated with radioligand therapy in men with mCRPC; and Apply practical strategies to monitor and manage adverse events associated with radioligand therapy in men with mCRPC.
-
George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action
Visit https://www.peervoice.com/BSG860 to view the entire programme with slides. After completing “George Kassianos, CBE, MD (Hons), FRCGP / Gili Regev-Yochay, MD - Current 2024 COVID-19 Vaccination Campaign: The Evidence Supporting the Call to Action”, participants will be able to: Summarise the evidence supporting the need for the current 2024 COVID-19 vaccination campaign for older adults and vulnerable individuals; and Outline the key recommendations by the World Health Organization (WHO) and European Centre for Disease Prevention and Control (ECDC) on the current 2024 COVID-19 vaccination roll-out.
-
Marwan Fakih, MD - The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line
Visit https://www.peervoice.com/SSC860 to view the entire programme with slides. After completing “Marwan Fakih, MD - The Science and the Art of Sequencing Therapies in Advanced CRC Beyond the Second Line”, participants will be able to: Identify patients with advanced colorectal cancer (CRC) with disease progression who should be treated with later lines of therapy; Recognize patient-specific characteristics which guide choice and planning of later lines of treatment for advanced CRC; and Propose treatment regimens for patients with advanced CRC which has progressed on earlier lines of therapy.
-
Amy E. DeZern, MD, MHS - Small Words Make Large Differences: Best Practices in Supporting MDS Patients Across All Stages of Their Journey
Visit https://www.peervoice.com/BJP860 to view the entire programme with slides. After completing “Amy E. DeZern, MD, MHS - Small Words Make Large Differences: Best Practices in Supporting MDS Patients Across All Stages of Their Journey”, participants will be able to: Identify the data required to calculate a patient’s myelodysplastic syndrome (MDS) risk status by utilizing the Molecular International Prognostic Scoring System (IPSS-M); Identify patients with intermediate-risk MDS who may benefit from treatment for higher-risk MDS; Formulate initial treatment plans for high-risk MDS (HR-MDS) based on individual patient factors; and Identify opportunities to provide support to patients with HR-MDS beyond pharmacological management.
-
Marwan Fakih, MD - Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC
Visit https://www.peervoice.com/AQR860 to view the entire programme with slides. After completing “Marwan Fakih, MD - Expert Lines of Thought in Sequencing Later Lines of Therapy in Advanced CRC”, participants will be able to: Describe current evidence-based standards of care in the management of advanced colorectal cancer (CRC); Evaluate emerging efficacy and safety data for treatment of advanced CRC beyond the second line; and Apply clinical data and guidelines to individualized sequencing of lines of therapy in advanced CRC.